Meet Dr. Nicole Verdun, New Director of FDA CBER OTP, at the Policy Summit

ASGCT is excited to announce that Dr. Nicole Verdun, Director of FDA CBER Office of Therapeutic Products (OTP), will join this year’s Policy Summit in a fireside chat titled "Updates on the Transition from Office of Tissues and Advanced Therapies (OTAT) to Office of Therapeutic Products (OTP)"

Dr. Verdun’s session will kick off the Policy Summit on Sept. 18 with a discussion on the new super office at FDA CBER, including plans to accommodate substantial growth in the CGT field and how to continue supporting development of innovative, novel products under their regulatory jurisdiction. Policy Summit attendees will also have the opportunity to ask questions of the new Director.

After the fireside chat, stick around for other regulatory-focused sessions on standards for CGTs, manufacturing policy realities, patient-centered clinical development, and more!

ASGCT's Policy Summit connects you with policy and industry leaders in the field where you'll learn from a variety of stakeholder perspectives and how they inform regulatory, legislative, and payment policies that impact gene and cell therapy development. Join us virtually or in person!

In-person registration will be extremely limited - so register today to secure your spot in Washington, DC!

Related Articles